Drug Trial Radar · NCT07268222
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Nov 1, 2026
Study completion Nov 25, 2027
Sponsor
- Lead sponsor
- Laikο General Hospital, AthensAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the efficacy and safety of the two 11β-hydroxylase inhibitors-metyrapone and osilodrostat-in patients with MACS. Primary outcome To compare the efficacy (biochemical and clinical) of the two 11β-hydroxylase inhibitors (CYP11B1), metyrapone and osilodrostat, in patients with MACS not treated surgically (mainly bilateral adenomas or adrenal hyperplasias), as well as their side effects at time 0-, 3- and 6-months post-treatment. Secondary outcome To evaluate alterations in clinical parameters (Blood Pressure, Body Mass Index-BMI), metabolic parameters (fasting blood glucose, insulin, Hb1Ac, HOMA, OGTT and lipids levels) at time 0-, 3- and 6-month after the initiation of the treatment and their effect on Bone Mineral Density (BMD) 1 year post-diagnosis
Conditions
- Mild Autonomous Cortisol Secretion (MACS)
Interventions
Metyrapone 250 mg Oral TabletsDrug
metyrapone( 250 -750 mg) vs. osilodrostat (1-3 mg) vs. surgery vs watch and wait strategy in the management of patients with MACS
Osilodrostat 1 MGDrug
administration of 1-3 mg of osilodrostat at 19.00
adrenalectomyProcedure
Surgery performed in patients with MACS
Watch and waitOther
Follow-up
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the efficacy of metyrapone and osilodrostatTime frame: Baseline ( at t=0), at t=3 months and at =6 months
- Comparison of the efficacy of metyrapone and osilodristatTime frame: Baseline (at t= 0), at t= 3 months and t= 6 months
- Comparison of the efficacy of metyrapone and osilodristatTime frame: Baseline ( at t=0), at t=3 months and at t=6 months
- Comparison of the efficacy of metyrapone and osilodristatTime frame: Baseline ( at t=0), at t=3 months and at =6 months
- Comparison of metyrapone and osilodrostat efficacyTime frame: Baseline (at t=0), at t=3 months , at t =6 months
- Comparison of metyrapone and osilodrostat in terms of alterations of metabolic parametersTime frame: Baseline (t=0), at t= 3months, at t=6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laikon General Hospital
Athens, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.